JPMorgan Chase & Co. Reaffirms Neutral Rating for GlaxoSmithKline PLC (GSK)
GlaxoSmithKline PLC (NYSE:GSK)‘s stock had its “neutral” rating reissued by stock analysts at JPMorgan Chase & Co. in a research note issued to investors on Wednesday.
A number of other research firms have also commented on GSK. Citigroup Inc. restated a “buy” rating on shares of GlaxoSmithKline PLC in a research note on Wednesday, July 27th. HSBC reiterated a “buy” rating on shares of GlaxoSmithKline PLC in a research note on Monday, September 12th. Zacks Investment Research upgraded shares of GlaxoSmithKline PLC from a “sell” rating to a “hold” rating in a research note on Monday, July 25th. Shore Capital reiterated a “hold” rating on shares of GlaxoSmithKline PLC in a research note on Wednesday, August 17th. Finally, Bank of America Corp. reiterated a “buy” rating and set a $48.00 price target on shares of GlaxoSmithKline PLC in a research note on Wednesday, June 22nd. Three investment analysts have rated the stock with a sell rating, ten have given a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the stock. The stock presently has an average rating of “Hold” and an average price target of $47.86.
GlaxoSmithKline PLC (NYSE:GSK) opened at 41.76 on Wednesday. GlaxoSmithKline PLC has a 1-year low of $37.82 and a 1-year high of $45.58. The firm has a 50-day moving average of $43.03 and a 200-day moving average of $42.98. The stock has a market capitalization of $101.50 billion, a price-to-earnings ratio of 2610.00 and a beta of 0.89.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/19/jpmorgan-chase-co-reaffirms-neutral-rating-for-glaxosmithkline-plc-gsk.html
The firm also recently announced a dividend, which was paid on Thursday, October 13th. Shareholders of record on Friday, August 12th were paid a $0.494 dividend. The ex-dividend date of this dividend was Wednesday, August 10th. GlaxoSmithKline PLC’s dividend payout ratio (DPR) is presently 6,166.67%.
A number of hedge funds have recently bought and sold shares of the stock. M&R Capital Management Inc. acquired a new stake in GlaxoSmithKline PLC during the second quarter worth about $109,000. Quadrant Capital Group LLC boosted its stake in GlaxoSmithKline PLC by 6.4% in the second quarter. Quadrant Capital Group LLC now owns 2,725 shares of the pharmaceutical company’s stock worth $111,000 after buying an additional 163 shares during the period. Thrivent Financial for Lutherans boosted its stake in GlaxoSmithKline PLC by 3.8% in the second quarter. Thrivent Financial for Lutherans now owns 2,651 shares of the pharmaceutical company’s stock worth $115,000 after buying an additional 96 shares during the period. SevenBridge Financial Group LLC acquired a new stake in GlaxoSmithKline PLC during the second quarter worth about $116,000. Finally, Cribstone Capital Management LLC acquired a new stake in GlaxoSmithKline PLC during the second quarter worth about $117,000. Hedge funds and other institutional investors own 8.80% of the company’s stock.
GlaxoSmithKline PLC Company Profile
GlaxoSmithKline plc (GSK) is a healthcare company. The Company is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products. The Company’s segments include Pharmaceuticals, Pharmaceuticals R&D, Vaccines and Consumer Healthcare.
Receive News & Ratings for GlaxoSmithKline PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline PLC and related companies with MarketBeat.com's FREE daily email newsletter.